TY - JOUR
T1 - Bariatric surgery for type 2 diabetes
AU - Dixon, John B.
AU - Le Roux, Carel W.
AU - Rubino, Francesco
AU - Zimmet, Paul
N1 - Funding Information:
JBD has received research funding and support from Allergan and Scientific Intake. He is on the Medical Advisory Board for Nestlé Australia and has received consultancy fees from Allergan and Metagenics. FR has received research grants from Covidien and Roche. He is a member of the scientific advisory board of NGM Biopharmaceuticals. PZ has received a consultancy fee from Covidien in the past. He has received speakers' fees from Metacure, Novo Nordisk, GlaxoSmithKline, Abbott, Eli Lilly, ResMed, and Novartis. CWlR declares that he has no conflicts of interest.
Funding Information:
JBD receives a research fellowship from the National Health and Medical Research Council of Australia. We thank Toni McGee for her assistance with the collation, review, and submission of the article.
PY - 2012/6
Y1 - 2012/6
N2 - Bariatric surgery provides substantial, sustained weight loss and major improvements in glycaemic control in severely obese individuals with type 2 diabetes. However, uptake of surgery in eligible patients is poor, and the barriers are difficult to surmount. We examine the indications for and efficacy and safety of conventional bariatric surgical procedures and their effect on glycaemic control in type 2 diabetes. How surgical gastrointestinal interventions achieve these changes is of great research interest, and is evolving rapidly. Old classifications about restriction and malabsorption are inadequate, and we explore understanding of putative mechanisms. Some bariatric procedures improve glycaemic control in people with diabetes beyond that expected for weight loss, and understanding this additional effect could provide insights into the pathogenesis of type 2 diabetes and assist in the development of new procedures, devices, and drugs both for obese and non-obese patients.
AB - Bariatric surgery provides substantial, sustained weight loss and major improvements in glycaemic control in severely obese individuals with type 2 diabetes. However, uptake of surgery in eligible patients is poor, and the barriers are difficult to surmount. We examine the indications for and efficacy and safety of conventional bariatric surgical procedures and their effect on glycaemic control in type 2 diabetes. How surgical gastrointestinal interventions achieve these changes is of great research interest, and is evolving rapidly. Old classifications about restriction and malabsorption are inadequate, and we explore understanding of putative mechanisms. Some bariatric procedures improve glycaemic control in people with diabetes beyond that expected for weight loss, and understanding this additional effect could provide insights into the pathogenesis of type 2 diabetes and assist in the development of new procedures, devices, and drugs both for obese and non-obese patients.
UR - https://www.scopus.com/pages/publications/84862271958
U2 - 10.1016/S0140-6736(12)60401-2
DO - 10.1016/S0140-6736(12)60401-2
M3 - Review article
C2 - 22683132
AN - SCOPUS:84862271958
SN - 0140-6736
VL - 379
SP - 2300
EP - 2311
JO - The Lancet
JF - The Lancet
IS - 9833
ER -